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Introduction
Type 2 diabetes is a significant public health issue.1,2 As of 
2012, approximately 26 million US adults aged 20 years or 
older have been diagnosed with diabetes; African Americans 
are disproportionately affected compared with non-Hispanic 
whites with 18.7% (4.9 million) of all African Americans diag-
nosed with type 2 diabetes compared with only 7.1% of non-
Hispanic whites.2 In addition, African Americans are also 
more likely to experience increased morbidity related to type 2 
diabetes such as diabetic retinopathy and kidney disease.2
Although the cause of type 2 diabetes is not completely 
understood, there is a strong genetic component to type 2 
diabetes risk as evidenced by family history and concordance 
studies among twins.3 The advent of genome-wide associa-
tion studies (GWAS) has resulted in the identification of 
robust associations with common genetic risk variants for 
type 2 diabetes and related traits; risk prediction models 
incorporating these variants have only improved risk predic-
tion marginally.4–21 A better understanding of how these 
known genetic variants affect type 2 diabetes, for example, 
via β-cell dysfunction (BCD) or increased insulin resistance 
(IR) has allowed for the development of pathway-specific 
genetic risk scores (GRSs); yet, few studies have evaluated 
their association with type 2 diabetes risk.7 Cardiometabolic 
traits such as obesity, hypertension, hyperlipidemia, and 
hyperglycemia are established type 2 diabetes risk factors; 
however, it remains to be seen whether type 2 diabetes risk is 
modified in the presence of both cardiometabolic and genetic 
risk factors.22 With the high prevalence of IR and lower 
insulin sensitivity in African Americans, risk variants related 
to glucose homeostasis may be of particular importance 
among those with existing cardiometabolic risk factors.23–25 
Given the current public health crisis posed by type 2 diabe-
tes coupled with the difficulty in lowering and maintaining 
cardiometabolic risk factors, the early identification of at-
risk individuals prior to the onset of cardiometabolic risk 
factors is an important public health goal.
In this study, we combined data from 4 prospective cohort 
studies to (1) determine whether the cumulative effect of 22 
glucose homeostasis genetic risk variants combined into GRSs 
related to BCD, IR, or both (BCD/IR) is associated with inci-
dent type 2 diabetes; (2) evaluate the association of each GRS 
on type 2 diabetes risk within cardiometabolic strata; and (3) 
assess whether the GRSs improve type 2 diabetes risk predic-
tion beyond established risk factors.
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Methods
Description of studies
Data from the Jackson Heart Study ( JHS), the Multi-Ethnic 
Study of Atherosclerosis (MESA), the Atherosclerosis Risk in 
Communities Candidate Gene Association Resource (ARIC_
CARe), and the Coronary Artery Risk Development in Young 
Adults (CARDIA) were obtained from the database of 
Genotypes and Phenotypes (dbGaP). All 4 studies have been 
previously described elsewhere.26–29 Briefly, JHS is one of the 
largest prospective cohort studies assessing cardiovascular risk 
in African Americans. Noninstitutionalized participants aged 
35 to 84 years living in the Jackson, Mississippi metropolitan 
statistical area, were eligible at the time of enrollment. Data 
were available for 934 participants for the initial examination 
and a second follow-up examination in addition to yearly fol-
low-up contact information yielding 12 years of follow-up.26 
MESA included community-dwelling participants aged 45 to 
84 years without any known clinical cardiovascular disease at 
the time of enrollment. Recruited from 6 different field centers 
throughout the United States, MESA participants were identi-
fied as European American, African American, Hispanic, or of 
Chinese descent. Complete data for 940 African Americans 
were available from 4 clinic examinations beginning in 2000.27 
ARIC_CARe is a part of the larger ARIC study assessing car-
diovascular disease risk in close to 15 000 African Americans 
and European Americans. Participants aged 45 to 64 years were 
recruited from 4 US communities and have undergone 4 clini-
cal examinations over a 10-year period as well as yearly follow-
up via telephone for a total of 25 years.28 Complete follow-up 
data were available for 1991 African American participants. 
Finally, beginning in 1985-1986, CARDIA has enrolled 
African Americans and European Americans from 4 US com-
munities. Participants’ ages ranged from 18 to 30 years at 
enrollment, and data were available from 7 clinical examina-
tions spanning 20 years for 757 African American partici-
pants.29 Participants of all 4 studies provided informed consent 
and each original study had institutional review board approval. 
Our study was approved by the Indiana University Institutional 
Review Board.
Eligibility criteria
To be included in this study, participants were required to self-
identify as African American, be at least 18 years of age, and be 
free of type 2 diabetes at baseline. Those with baseline type 2 
diabetes or missing type 2 diabetes status were excluded. In 
addition, participants with missing genetic, demographic, and 
clinical risk factors at baseline were excluded.
Type 2 diabetes outcome
Incident type 2 diabetes was the main outcome variable in 
the study and was measured in follow-up examinations or 
questionnaires. The studies MESA, ARIC, JHS, and CARDIA 
determined type 2 diabetes status at baseline and during fol-
low-up examinations using fasting plasma glucose (FPG) with 
a cutoff greater than 126 mg/dL (7.0 mmol/L). JHS also used 
annual follow-up questionnaires to establish type 2 diabetes 
status in between examinations by asking participants whether 
they had diabetes.
Clinical risk factors
Baseline cardiometabolic risk factor cut points were deter-
mined using clinically meaningful standards and were defined 
as high body mass index (BMI) (≥30 kg/m2), hypertension 
(≥140 mm Hg systolic blood pressure [SBP]), low fasting high-
density lipoprotein (HDL) (≤40 mg/dL in men and ≤50 mg/
dL in women), fasting hypertriglyceridemia (≥150 mg/dL), 
and fasting hyperglycemia (≥100 mg/dL).30 A positive family 
history of type 2 diabetes was noted if one or both parents were 
reported to have type 2 diabetes. Race was determined via 
self-report.
Genetic risk score
We chose 22 GWAS-identified type 2 diabetes single-nucleo-
tide polymorphisms reported to affect β-cell function (15 
SNPs) or IR (7 SNPs). Previously reported results from either 
homeostasis model assessment-B or β-cell function indices 
such as the insulinogenic index or acute insulin response were 
used to determine the potential physiologic impact of each 
SNP on β-cell function and/or IR.7,10 Each of the 4 studies 
used the Affymetrix 6.0 platform; when the original SNPs 
reported in GWAS were not available, suitable proxy SNPs 
with an r2 value greater than or equal to 0.8 in HapMap African 
Ancestry in Southwest USA (ASW) or Yoruba in Ibadan, 
Nigeria (YRI) populations were chosen. Assuming an additive 
genetic model for each SNP, the number of risk alleles present 
for each SNP (ranging from 0 to 2 risk alleles) was summed 
across all loci to create a GRS for each individual. Similarly, 
both the BCD and IR GRSs were created as the sum of the 
number of risk loci related to BCD and IR, respectively. Due to 
the lack of sufficiently large GWAS studies to determine locus 
effect sizes for type 2 diabetes risk variants in African 
Americans, we were not able to use weighted GRSs. However, 
previous studies have shown no difference between weighted 
and unweighted GRSs.7
Admixture analysis
To control for potential confounding due to admixture in 
African Americans, 47 ancestry informative markers (AIMs) 
common across all 4 studies were used to determine indi-
vidual admixture using Frappe (version 1.1) in a 2-popula-
tion model.31,32 These AIMs were chosen based on their 
availability on Affymetrix 6.0 platform in addition to their 
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ability to maximize European and African allele frequency 
differences. Admixture estimates were used as a covariate in 
all analyses.
Statistical analyses
Baseline continuous variables were summarized by mean 
(SD) and compared using analysis of variance. Categorical 
variables were summarized by frequency (%) and compared 
using χ2 tests. Time to onset of type 2 diabetes (in months) 
was defined as the time from baseline to follow-up when type 
2 diabetes was diagnosed. Logistic regression models were 
used to investigate the association between each individual 
SNP and incident type 2 diabetes, controlling for age, sex, and 
admixture. Cox proportional hazard models were used to 
associate baseline clinical covariates and GRSs to time of dia-
betes onset. The proportional hazard assumption was checked 
using the Schoenfeld residuals test.33 The estimated linear 
term in the Cox model was treated as an overall risk score, 
which was used to discriminate people at high risk for diabe-
tes from those who were not. Sensitivity, specificity, and area 
under the receiver operating characteristic curve of diabetes 
incidence were estimated using a nonparametric method, 
with confidence intervals constructed using the bootstrap 
method. C-statistics and continuous net reclassification 
improvement (NRI) for models with and without GRS were 
estimated and tested using the method by Pencina.34,35 All 
analyses were performed in SAS 9.4 (SAS Inc., Cary, NC, 
USA) and R 3.0.36
Results
Study sample characteristics
Among all 4 studies used in these analyses, there were a 
total of 4622 African Americans free of type 2 diabetes at 
baseline. Table 1 shows baseline participant characteristics by 
study. Overall, the mean baseline age was 49.3 (SD: 
±14.3) years and the mean FPG was 92.3 (SD: ±11.9) mg/
dL. There were more women than men (59% vs 41%), and 
only 31% reported a family history of diabetes. Compared 
with the other 3 studies, CARDIA participants tended to be 
younger (mean age: 24.4 years, SD: ±3.9) and had a more 
favorable risk profile with respect to clinical risk factors and 
covariates such as family history of diabetes (16.9%) and 
FPG (80.9 mg/dL, SD: ±8.8). Over a mean follow-up time 
of 7.7 years, there were a total of 679 incident type 2 diabetes 
cases giving a cumulative incidence of 14.7%. Finally, the 
mean African ancestry proportion in the overall sample was 
0.80 (SD: ±0.17).
Individual genetic risk variants
Supplemental Table 1 lists the SNPs used in our analyses, their 
risk alleles and frequencies in the overall study population, and 
the association results. We assessed 22 SNPs related to glucose 
homeostasis (7 SNPs associated with IR and 15 SNPs related 
to BCD). Of these 22 SNPs, only CDC123 rs4747969 was 
significantly associated with type 2 diabetes after adjustment 
for age, sex, and African admixture (odds ratio = 1.176, 95% 
confidence interval [CI]: 1.031-1.342), although most of the 
remaining SNP results were consistent in direction and effect 
size with previously published results.
GRSs and type 2 diabetes
Incident type 2 diabetes cases had a higher mean BCD GRS 
and BCD/IR GRS as compared with controls (19.4 vs 19.1 
and 28.2 vs 27.8, P < .05 for both), whereas the mean IR 
GRS did not differ significantly between cases and controls 
(8.8 vs 8.7). Both the BCD GRS and the BCD/IR GRS were 
Table 1. Baseline characteristics of study participants by cohort after exclusion of those with baseline type 2 diabetes.










P VALUE FOR 
DIFFERENCE 
BETWEEN STUDIES
Gender (% male) 1897 (41.0) 446 (47.5) 772 (38.8) 313 (41.4) 366 (39.2) <.0001
Family history of diabetes (% yes) 1432 (31.0) 394 (41.9) 491 (24.7) 128 (16.9) 419 (44.9)  <.0001
Age, y 49.3 (14.3) 61.6 (10.3) 53.0 (5.7) 24.4 (3.9) 48.9 (11.7) <.0001
Systolic blood pressure, mm Hg 124.6 (19.6) 131.0 (21.1) 127.3 (19.9) 110.8 (11.0) 123.5 (17.4) <.0001
HDL cholesterol, mg/dL 54.2 (16.2) 53.2 (15.4) 56.2 (17.9) 54.6 (13.1) 50.5 (14.6) <.0001
Triglycerides, mg/dL 97.0 (64.6) 99.6 (56.26) 106.3 (73.9) 65.9 (35.3) 99.7 (62.1) <.0001
Fasting plasma glucose, mg/dL 92.3 (11.9) 90.6 (10.8) 98.6 (9.9) 80.9 (8.8) 89.6 (10.0) <.0001
BMI, kg/m2 29.4 (6.5) 30.0 (5.9) 29.1 (5.9) 26.2 (6.0) 32.1 (7.4) <.0001
Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; HDL, high-density 
lipoprotein; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis.
Values are mean (SD) or counts (%).
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significantly associated with incident type 2 diabetes in models 
including standard clinical risk factors (hazard ratio 
[HR] = 1.037, 95% CI: 1.006-1.070 and HR = 1.029, 95% CI: 
1.002-1.057, respectively; Table 2).
Predictive ability of GRSs
The addition of any of the 3 GRS to a standard clinical risk 
factors–only model showed no improvement in the NRI or the 
C-statistics in the overall study cohort (Table 2 and Figure 1) 
or the cardiometabolic strata (Table 3) indicating no improve-
ment in the ability to predict incident type 2 diabetes beyond 
that of standard clinical risk factors.
Cardiometabolic risk factor analyses
We performed analyses stratified by cardiometabolic risk fac-
tors to determine whether the magnitude of the effect of the 
BCD or IR GRS differed within each cardiometabolic strata 
after adjusting for standard clinical risk factors (Table 3). In 
clinically healthy strata, the BCD GRS HRs were 1.054 (95% 
CI: 1.003-1.107) and 1.063 (95% CI: 1.026-1.101) in lean and 
normotensive individuals, respectively. In normoglycemic indi-
viduals, the IR GRS HR was 1.093 (95% CI: 1.001-1.194). In 
clinically unhealthy strata, the BCD GRS HRs were 1.060 
(95% CI: 1.012-1.111) and 1.071 (95% CI: 1.004-1.143) in 
low HDL and hypertriglyceridemic individuals, respectively 
(Table 3).
We compared baseline cardiometabolic profiles between 
cases and controls in each of the strata where the GRSs were 
significantly associated with type 2 diabetes to gain insight into 
which clinical risk factors were influencing this increased risk 
using International Diabetes Federation (IDF) cutoff values 
for metabolic syndrome.30 In the clinically unhealthy strata, 
cases had baseline cardiometabolic profiles that met the criteria 
for metabolic syndrome (Table 4). For example, within the low 
HDL and hypertriglyceridemia strata, cases had BMI values 
that met the abdominal obesity criterion in addition to 2 other 
factors; for the low HDL stratum, cases had reduced HDL and 
raised FPG, whereas cases in the hypertriglyceridemia stratum 
had both elevated triglycerides and FPG. In contrast, none of 
the cases within the clinically healthy strata met the IDF crite-
ria for metabolic syndrome (Table 5). This suggests that GRSs 
alone are significant predictors before the onset of the clinical 
risk factors.
Discussion
We observed a significant increase in type 2 diabetes risk with 
increased risk allele load in analyses using a GRS based on 
variants related to BCD but not IR in the overall study cohort. 
When we stratified our study cohort by cardiometabolic risk 
factors, we found that the IR GRS was significantly associated 
with 9% increased type 2 diabetes risk only among individuals 
Table 2. Genetic risk scores associated with type 2 diabetes incidence and prediction performance.
WITHOUT GRS GRS-IR GRS-BCD GRS-BCD/IR
Entire study cohort (n = 4622)
HR (95% CI) — 1.01 (0.96 to 1.06) 1.037 (1.006 to 1.070) 1.029 (1.002 to 1.057)
C-statistics (95% CI) 0.811 (0.796 to 0.828) 0.811 (0.795 to 0.829) 0.812 (0.795 to 0.829) 0.812 (0.795 to 0.829)
Continuous NRI (95% CI) — 0.014 (−0.076 to 0.068) 0.014 (−0.068 to 0.065) 0.002 (−0.104 to 0.056)
Abbreviations: BCD, β-cell dysfunction; GRS, genetic risk score; HR, hazard ratio; IR, insulin resistance; NRI, net reclassification index.
A clinical model without the GRS is compared with 3 different GRSs in the whole cohort using Cox proportional hazards modeling and continuous net reclassification 
index analyses: GRS-IR includes SNPs associated with IR, GRS-BCD includes SNPs associated with β-cell function, and GRS-BCD/IR includes both IR and β-cell 
function SNPs. The clinical model includes the following baseline variables: age, sex, family history of diabetes, BMI, SBP, HDL, triglycerides and fasting glucose, cohort, 
and admixture.
Bold values signify P value < 0.05.
Figure 1. Receiver operating characteristic (ROC) curves for each of the 
GRS for the combined study population. Incident type 2 diabetes risk 
prediction is shown at 5 years without genetic risk information (noGRS) 
and with the addition of each of the 3 GRSs (GRSBC, genetic risk score 
β-cell dysfunction; GRSIR, genetic risk score insulin resistance; GRSall, 
genetic risk score BCD/IR). The graph plots sensitivity vs (1 − specificity). 
The area under the curve (AUC) corresponds to the C-statistics for each 
of the 4 models. The model without genetic risk information includes the 
following variables: age, sex, family history of diabetes, body mass index, 
systolic blood pressure, high-density lipoprotein, triglycerides and fasting 
glucose, cohort, and admixture.
TP: true positive (sensitivity); FP: false positive (1-specificity).
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Table 3. Genetic risk scores associated with type 2 diabetes incidence and prediction performance within cardiometabolic strata.
WITHOUT GRS GRS-IR GRS-BCD
Lean (BMI < 30 kg/m2) (n = 2819)
 HR (95% CI) — 1.010 (0.927 to 1.100) 1.054 (1.003 to 1.107)
 C-statistics 0.815 0.817 0.820
 Difference in AUC (95% CI) — −0.002 (−0.004 to 0.002) −0.005 (−0.010 to 0.005)
Obese (BMI ≥ 30 kg/m2) (n = 1803)
 HR (95% CI) — 1.004 (0.939 to 1.074) 1.040 (1.000 to 1.081)
 C-statistics 0.770 0.770 0.770
 Difference in AUC (95% CI) — 0.000 (−0.001 to 0.001) 0.000 (−0.005 to 0.008)
Normotensive (SBP < 140 mm Hg) (n = 3753)
 HR (95% CI) — 1.010 (0.950 to 1.074) 1.063 (1.026 to 1.101)
 C-statistics 0.809 0.809 0.811
 Difference in AUC (95% CI) — 0.000 (−0.001 to 0.001) −0.002 (−0.006 to 0.003)
Hypertensive (SBP ≥ 140 mm Hg) (n = 869)
 HR (95% CI) — 1.017 (0.914 to 1.130) 0.999 (0.937 to 1.064)
 C-statistics 0.781 0.781 0.779
 Difference in AUC (95% CI) — 0.000 (−0.004 to 0.003) 0.002 (−0.008 to 0.014)
Normal HDL (≥40 mg/dL [men] and ≥50 mg/dL [women]) (n = 3218)
 HR (95% CI) — 0.997 (0.932 to 1.067) 1.027 (0.986 to 1.070)
 C-statistics 0.805 0.805 0.802
 Difference in AUC (95% CI) — 0.000 (−0.002 to 0.001) 0.003 (−0.003 to 0.008)
Low HDL (<40 mg/dL [men] and <50 mg/dL [women]) (n = 1404)
 HR (95% CI) — 1.034 (0.950 to 1.126) 1.060 (1.012 to 1.111)
 C-statistics 0.796 0.797 0.798
 Difference in AUC (95% CI) — −0.001 (−0.002 to 0.001) −0.002 (−0.007 to 0.005)
Normal triglycerides (<150 mg/dL) (n = 4073)
 HR (95% CI) — 1.031 (0.970 to 1.097) 1.034 (0.999 to 1.071)
 C-statistics 0.812 0.813 0.813
 Difference in AUC (95% CI) — −0.0004 (−0.0015 to 0.0007) −0.001 (−0.005 to 0.004)
Hypertriglyceridemia (≥150 mg/dL) (n = 549)
 HR (95% CI) — 0.981 (0.882 to 1.090) 1.071 (1.004 to 1.143)
 C-statistics 0.742 0.741 0.752
 Difference in AUC (95% CI) — 0.0004 (−0.0029 to 0.0057) −0.010 (−0.028 to 0.005)
Normoglycemia (FPG < 100 mg/dL) (n = 3437)
 HR (95% CI) — 1.093 (1.001 to 1.194) 1.040 (0.990 to 1.091)
 C-statistics 0.671 0.672 0.672
 Difference in AUC (95% CI) — −0.001 (−0.003 to 0.001) −0.001 (−0.012 to 0.009)
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who were normoglycemic at baseline. The BCD GRS was 
associated with 5% to 7% increased type 2 diabetes risk among 
those belonging to each of the following baseline-derived 
strata: lean, normotensive, low HDL, and hypertriglyceridemia. 
The C-statistics and net risk reclassification did not show the 
GRSs improved risk prediction over standard clinical risk 
Table 4. Characteristics of participants by case/control status in clinically unhealthy cardiometabolic strata in which the genetic risk scores are 
associated with incident type 2 diabetes.
CLINICAL RISk FACTOR LOW HDL (<40 MG/DL [MEN] AND 
<50 MG/DL [WOMEN]) (N = 1404) (N = 289 
T2D CASES VS N = 1115 CONTROLS)
P VALUE* HYPERTRIGLYCERIDEMIA 
(≥150 MG/DL) (N = 549) (N = 161 T2D 
CASES VS N = 388 CONTROLS)
P VALUE*
Systolic blood pressure, mm Hg 127.1 (19.3) vs 124.3 (19.6) .0283 132.0 (20.8) vs 129.6 (19.2) .1833
HDL cholesterol, mg/dL 38.1 (6.2) vs 39.4 (6.0) .0010 44.5 (15.1) vs 43.6 (13.7) .4981
Triglycerides, mg/dL 148.5 (143.2) vs 118.7 (71.9) .0007 231.1 (171.3) vs 207.7 (77.0) .0975
Fasting plasma glucose, mg/dL 102.8 (12.0) vs 91.8 (10.8) <.0001 104.7 (11.2) vs 95.6 (10.5) <.0001
BMI, kg/m2 33.3 (6.6) vs 30.7 (6.4) <.0001 32.6 (5.7) vs 29.9 (5.6) <.0001
Abbreviations: BCD, β-cell dysfunction; BMI, body mass index; GRS, genetic risk score; HDL: high-density lipoprotein; T2D, type 2 diabetes.
Only the BCD GRS was associated with incident type 2 diabetes within the low-HDL and hypertriglyceridemia strata.
*P value is for comparison between cases and controls.
Table 5. Characteristics of participants by case/control status in clinically healthy cardiometabolic strata in which the genetic risk scores are 
associated with incident type 2 diabetes.
CLINICAL RISk 
FACTOR
LEAN (BMI < 26 kG/
M2) (N = 1504) (N = 92 





(SBP < 140 MM HG) 
(N = 3753) (N = 507 T2D 





(FPG < 100 MG/DL) 
(N = 3437) (N = 255 T2D 






124.4 (18.4) vs 120.1 (19.2) .0372 120.1 (10.8) vs 116.9 (11.9) <.0001 126.6 (19.1) vs 122.6 (19.0) .0011
HDL cholesterol 
(mg/dL)
52.1 (15.0) vs 59.7 (18.1) <.0001 49.2 (14.1) vs 54.8 (16.0) <.0001 50.2 (14.8) vs 55.5 (16.2) <.0001
Triglycerides,  
mg/dL
111.4 (81.7) vs 81.2 (46.2) .0007 125.4 (115.1) vs 89.4 (51.9) <.0001 112.0 (92.1) vs 87.8 (50.1) <.0001
FPG, mg/dL 98.5 (13.6) vs 87.7 (10.8) <.0001 102.0 (13.0) vs 89.7 (10.6) <.0001 89.2 (8.7) vs 86.8 (7.8) <.0001
BMI, kg/m2 23.8 (1.9) vs 23.1 (2.2) .0028 32.7 (6.8) vs 28.6 (6.1) <.0001 32.6 (7.1) vs 28.6 (6.3) <.0001
Abbreviations: BCD, β-cell dysfunction; BMI, body mass index; FPG: fasting plasma glucose; GRS, genetic risk score; HDL: high-density lipoprotein; IR, insulin resistance; 
SBP: systolic blood pressure; T2D, type 2 diabetes.
The BCD GRS was associated with incident type 2 diabetes within lean BMI and normotensive strata and the IR GRS was associated with incident type 2 diabetes 
within the normoglycemia stratum.
*P value is for comparison between cases and controls.
WITHOUT GRS GRS-IR GRS-BCD
Hyperglycemia (FPG ≥ 100 mg/dL) (n = 1185)
 HR (95% CI) — 0.963 (0.901 to 1.030) 1.034 (0.995 to 1.074)
 C-statistics 0.717 0.715 0.713
 Difference in AUC (95% CI) — 0.002 (−0.001 to 0.003) 0.004 (−0.005 to 0.012)
Abbreviations: AUC, area under the curve; BCD, β-cell dysfunction; BMI, body mass index; FPG, fasting plasma glucose; GRS, genetic risk score; HDL, high-density 
lipoprotein; HR, hazard ratio; IR, insulin resistance; SBP, systolic blood pressure; T2D, type 2 diabetes.
A clinical model without the GRS is compared with 2 different GRSs in the whole cohort using Cox proportional hazards modeling and continuous net reclassification 
index analyses: GRS-IR includes SNPs associated with insulin resistance and the GRS-BCD includes SNPs associated with β-cell function. The difference in AUC 
compares clinical models without a GRS to models with each individual GRS. Model without GRS includes the following variables at baseline: age, sex, family history 
of diabetes, BMI, SBP, HDL, triglycerides and fasting glucose, cohort, and admixture. Within each cardiometabolic strata, the trait corresponding to that strata was not 
included in the model.
Bold values signify P value < 0.05.
Table 3. (Continued)
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factors in both the overall study cohort and within each of the 
cardiometabolic strata.
Participants in the clinically healthy strata (lean, normoten-
sive, or normoglycemic) where the BCD or IR GRS were sig-
nificantly associated with increased type 2 diabetes risk overall 
demonstrated a more favorable clinical profile at baseline such 
as younger age, lower BMI, and lower triglycerides. Furthermore, 
the type 2 diabetes cases within these strata had clinical profiles 
which would not necessarily identify them as being at risk for 
type 2 diabetes. On average, their SBP, HDL, triglycerides, 
FPG, and BMI did not exceed metabolic syndrome cutoffs as 
determined by the IDF criteria. These results suggest that cases 
with healthier baseline characteristics such as lower BMI 
(<30 kg/m2), normotension (<140 mm Hg), and normoglyce-
mia (<100 mg/dL) may have a stronger genetic susceptibility to 
type 2 diabetes thus explaining why we observed an increased 
risk for type 2 diabetes in otherwise clinically healthy strata.
Conversely, type 2 diabetes cases in the 2 dyslipidemic strata 
(low HDL and high triglycerides) where the BCD GRS was 
also significantly associated with type 2 diabetes did have val-
ues meeting the IDF criteria for metabolic syndrome in addi-
tion to higher BCD GRSs. It is possible that in addition to 
having an increased genetic risk for BCD, cases in these 
unhealthy dyslipidemic strata may be experiencing glucolipo-
toxicity where the combined effects of increased fatty acid lev-
els and elevated glucose negatively affect β-cell function and 
survival.37 Thus, those with dyslipidemia in combination with 
increased genetic risk load related to BCD could potentially 
benefit from early interventions targeting cardiometabolic 
traits such as dyslipidemia to prevent or delay type 2 diabetes 
onset by potentially preserving β-cell function.
The Diabetes Prevention Program (DPP) has already dem-
onstrated that type 2 diabetes can be delayed or prevented with 
interventions involving 5% to 7% weight loss through lifestyle 
and behavior changes.38 More recently, a genetic risk interven-
tion study of adults at high risk phenotypically for type 2 dia-
betes reported no significant difference in adherence to DPP 
by participants with elevated GRSs vs controls.39 Indeed, 
changing type 2 diabetes risk behaviors and maintaining them 
is difficult.40 Our results imply that genetic risk information 
could be used to identify at-risk individuals who appear to have 
a clinically favorable profile prior to the development of the 
risk factors for and the onset of type 2 diabetes. Thus, the 
potential public health impact could be significant given that 
early identification can delay or prevent type 2 diabetes onset 
through the use of prevention efforts tailored to individual spe-
cific cardiometabolic risk profiles.
Our results are consistent with previous research that has 
demonstrated increased type 2 diabetes risk with both path-
way-specific and type 2 diabetes–related GRSs among African 
Americans.7–9,16,20 Cooke et al,9 one of the only identified stud-
ies solely conducted among African Americans (n = 4045), 
observed a significant association between their GRS compris-
ing 17 SNPs and type 2 diabetes risk even after taking into 
account African American admixture. Waters et  al16 also 
observed an increased risk for type 2 diabetes with increasing 
risk alleles in both their multiethnic cohort and the African 
American subset. In contrast, after limiting their cohort to 
African Americans (n = 577), Hivert et al20 found no associa-
tion between their 34-SNP GRS and progression to diabetes 
among participants with baseline-impaired glycemic regula-
tion (HR = 0.98 per risk allele, 95% CI: 0.94-1.03). A more 
recent study by Vassy et  al8 used a 38-variant GRS in the 
CARDIA study, including both white and black participants, 
and reported a genotype risk score that significantly predicted 
incident type 2 diabetes (HR = 1.08 per risk allele, 95% CI: 
1.04-1.13). Nonetheless, when stratifying by race/ethnicity, 
discrimination did not improve.8 However, only 34% of their 
study population was African American and therefore it is pos-
sible that this smaller sample size limited their ability to assess 
the discriminatory ability of their risk prediction model.
More recent studies have begun to focus on pathway-spe-
cific GRSs to improve predictive performance as well as to bet-
ter understand the genetic influences that may affect the 
observed racial differences in type 2 diabetes risk. Vassy et al7 
and Klimentidis et al11 both evaluated GRSs based on multiple 
pathways. Similar to the work by Vassy et al,7 our BCD GRS 
predicted incident type 2 diabetes but only in the overall study 
cohort. Klimentidis et  al11 reported an association with their 
fasting insulin GRS and type 2 diabetes in African Americans 
but not with their fasting glucose GRS. This is consistent with 
our results of an increased type 2 diabetes risk with the IR 
GRS in the normoglycemic stratum in addition to findings of 
greater IR and secretion among African Americans.23–25
A limitation of the study was the use of baseline measure-
ments of clinical characteristics. Many clinical variables are not 
static but change over time in contrast to genetic variants 
which are stable over the life course. However, established risk 
prediction models using clinical variables such as the 
Framingham Risk Score have used baseline measurements in 
their models achieving a high level of predictive power.41 In 
addition, models containing only clinical risk factors should 
perform better over shorter time frames given their variable 
nature, whereas genetic-based models should do better with 
longer time frames. The mean follow-up time in our study was 
7.5 years; therefore, it is not unreasonable that our models per-
formed better with clinical variables. Other limitations involved 
the different study time periods during which diabetes classifi-
cation criteria changed along with different methods used to 
determine type 2 diabetes status in the included studies. 
Although all of the studies used clinical measures of fasting 
glucose to determine type 2 diabetes status at baseline or later 
examinations, self-reported physician-diagnosed type 2 diabe-
tes or self-reported diabetes medication use was also used to 
determine diabetes status. Although this could result in poten-
tial misclassification of diabetes status, validation studies in 
ARIC, for example, have shown that the reliability of self-
reported diabetes status is more than 92%.42 Finally, GRSs 
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themselves have limitations. For example, GRSs do not take 
into account the potential interactions between genes and the 
environment. Although we stratified our results by known car-
diometabolic risk factors to evaluate the effect of the GRS 
within these subgroups, we were not able to evaluate how 
unhealthy lifestyle behaviors such as diet and physical activity 
may interact with genetic risk. This remains an important 
future research goal. Another limitation concerning our GRS is 
that the SNPs used in our study account for only a small pro-
portion of diabetes heritability and may not include causal 
variants or SNPs in high linkage disequilibrium with causal 
variants in the African American population. Because African 
populations have shorter linkage disequilibrium blocks, it is 
possible that common variants may be missed in GWAS pri-
marily conducted in European populations; identification of 
causal variants specific to African and African American pop-
ulations may improve the GRS predictive ability in these 
populations.
Conclusions
Our results suggest that SNPs related to BCD and IR path-
ways may be important in type 2 diabetes risk prediction in 
African Americans. In addition, there is evidence that a genetic 
predisposition for BCD and/or IR may result in an increased 
risk for type 2 diabetes despite having a more favorable clinical 
profile with respect to cardiometabolic risk factors. Further 
work is needed to better characterize the effect of pathway-
specific genetic risk in these populations so that early identifi-
cation and intervention can occur prior to type 2 diabetes onset.
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